172 related articles for article (PubMed ID: 2715807)
1. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone.
Greidanus J; de Vries EG; Mulder NH; Sleijfer DT; Uges DR; Oosterhuis B; Willemse PH
J Clin Oncol; 1989 Jun; 7(6):790-7. PubMed ID: 2715807
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.
de Vries EG; Greidanus J; Mulder NH; Nieweg MB; Postmus PE; Schipper DL; Sleijfer DT; Uges DR; Willemse PH
J Clin Oncol; 1987 Sep; 5(9):1445-51. PubMed ID: 3476690
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of 14-day continuous intravenous infusion mitoxantrone.
Kreisle WH; Alberts DS; List AF; McCloskey T; Plezia P; Peng YM; George M
Anticancer Drugs; 1991 Jun; 2(3):251-9. PubMed ID: 1802019
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.
de Forni M; Lachau S; Huguet F; Canal P; Laurent G; Chevreau C; Roche H; Bugat R
Eur J Cancer; 1991; 27(6):735-9. PubMed ID: 1829914
[TBL] [Abstract][Full Text] [Related]
6. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
Yang J; Shi Y; Li C; Gui L; Zhao X; Liu P; Han X; Song Y; Li N; Du P; Zhang S
Cancer Chemother Pharmacol; 2014 Sep; 74(3):637-46. PubMed ID: 25034977
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
[TBL] [Abstract][Full Text] [Related]
9. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
Minami H; Shimokata K; Saka H; Saito H; Ando Y; Senda K; Nomura F; Sakai S
J Clin Oncol; 1993 Aug; 11(8):1602-8. PubMed ID: 8336196
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
13. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.
Shepherd FA; Evans WK; Blackstein ME; Fine S; Heathcote J; Langer B; Taylor B; Habal F; Kutas G; Pritchard KI
J Clin Oncol; 1987 Apr; 5(4):635-40. PubMed ID: 3031227
[TBL] [Abstract][Full Text] [Related]
17. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Attal M; Canal P; Schlaifer D; Chatelut E; Dezeuze A; Huguet F; Payen C; Pris J; Laurent G
J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
Tchekmedyian NS; Egorin MJ; Cohen BE; Kaplan RS; Poplin E; Aisner J
Cancer Chemother Pharmacol; 1986; 18(1):33-8. PubMed ID: 3757157
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]